Abstract
Background Mitral Valve Prolapse (MVP) is a prevalent valvular disorder linked to considerable morbidity and mortality, affecting approximately 2.4% of the general population. A prior genome association study linked LTBP2 to this trait. We report a knockout mouse with LTBP2 mutation demonstrating valve phenotype as well as a family with a novel mutation causing MVP
Methods Exome sequencing and segregation analysis were conducted on a large pedigree to identify mutations associated with MVP. Using CRISPR-Cas9 technology, two strains of mice were generated: one with a complete knockout (KO) of the LTBP2 gene and another with a knock-in (KI) mutation corresponding to the putative causative mutation. Echocardiography and histological examinations of valves were performed in the KO and the KI at the age of 6 months. Optical coherence tomography (OCT) and histological examination of the eyes was done at the same time. mRNA qPCR analysis for TGFβ signaling targets (periostin/POSTN, RUNX2, and CTGF) in valve tissues was analysed.
Results The LTBP2 rs117800773 V1506M mutation exhibited segregation with the MVP trait. LTBP2 KO mice had higher incidence of myxomatous changes by histology (7 of 9 of KO vs. 0 of 7 control animals, p=0.00186) and echocardiography (7 of 9 vs. 0 of 8, p=0.0011). LTBP2 Knock-in mice for the human mutation showed a significantly elevated myxomatous histological phenotype (8 of 8 vs. 0 of 9, p=0.00004) as well as by echocardiography (6 of 8 vs. 0 of 9, p=0.00123). KO mice demonstrated a significant increase in the depth of the anterior chamber as well as reduced visual acuity. LTBP2 KO mice demonstrated overexpression of both TGFβ signaling targets RUNX2 and periostin (P=0.0144 and P=0.001826, respectively).
Conclusion Animal models of LTBP2 KO and KI recapitulate MVP phenotype indicating that LTBP2 mutations are indeed causing myxomatous degeneration. Further, LTBP2 rs117800773 V1506M segregated with MVP in a large pedigree. Our data indicate the importance of LTBP2 in normal mitral valve function and that mutations in the gene care causing myxomatous valve.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The paper was supported by BSF grant 2017265, and Hadassah Medical Center bridge grant in 2021.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Hadassah Hebrew University Hospital in Jerusalem IRB and the Israeli Ministry of Health committee for genetic studies (0464-10-HMO)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.
Non-standard Abbreviations and Acronyms
- LTBP2
- Latent Transforming Growth Factor Beta Binding Protein 2
- MVP
- Mitral Valve Prolapse
- KO
- Knockout
- KI
- Knock-in
- WT
- wild type mRNA messenger RNA
- PCR
- polymerase chain reaction q
- PCR
- Quantitative polymerase chain reaction
- RUNX2
- Runx family transcription factor 2
- ECM
- extra-cellular matrix gRNA guide RNA
- CRISPR
- Clustered Regularly Interspaced Short Palindromic Repeats sgRNA single guide RNA
- SSC
- Sequence scan for crispr
- ssODN
- single-stranded oligodeoxynucleotides
- tracrRNA
- trans-activating CRISPR RNA
- crRNA
- CRISPR RNAs
- IDT
- Integrated DNA Technologies
- H&E
- Hematoxylin and eosin staining
- DAPI
- 4’,6-diamidino-2-phenylindole
- qRT-PCR
- Real-Time Quantitative Reverse Transcription PCR
- CTGF
- connective tissue growth factor
- GAPDH
- glyceraldehyde-3-phosphate dehydrogenase protein family
- MR
- mitral regurgitation
- GWAS
- genome-wide association study
- LTBPs
- Latent Transforming Growth Factor Beta Binding Proteins
- MFS
- Marfan syndrome
- FBN1
- Fibrillin1
- LAP
- latency-associated peptide
- OCT
- Optical coherence tomography
